Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2021-01
Main Authors: Alencar, Julio C, Souza, Heraldo P
Format: Article
Language:English
Subjects:
Correspondence
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Clinical infectious diseases
container_volume
creator Alencar, Julio C
Souza, Heraldo P
description
doi_str_mv 10.1093/cid/ciab056
format article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8344472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_8344472</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_83444723</originalsourceid><addsrcrecordid>eNqljEtOwzAQQC0EovxWXGAOgMGukzbdIJUUBBKCqq3YRk4ybY0cO3KcVmHVg8BFOE5PghdsWLMYzdM8zSPkkrNrzkbiplBlGJmzeHBATngshnQQj_hhYBYnNEpE0iOnTfPOGOcJi49JT4iYib6ITsj32DRbdOAtPKP3gVJrCnRGmRX4NcJU1uG4331ObJtrpHdamfIKZtKUtlIfGHiqZYG5peHTO6s1lrBwSmrYKr-GFxqs73TRNR6VQVhaFzxKX6HxYJcwxw06hHHReoQZNrVy0lvXwbwzpbMVQirbJlTzDtLXt6cJ5aP97uucHC2lbvDid5-R24f7RfpI6zavsCxC3Umd1U5V0nWZlSr7a4xaZyu7yRIRRdGwL_4d-AH9joXN</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Alencar, Julio C ; Souza, Heraldo P</creator><creatorcontrib>Alencar, Julio C ; Souza, Heraldo P</creatorcontrib><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciab056</identifier><identifier>PMID: 33503234</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Correspondence</subject><ispartof>Clinical infectious diseases, 2021-01</ispartof><rights>The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Alencar, Julio C</creatorcontrib><creatorcontrib>Souza, Heraldo P</creatorcontrib><title>Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”</title><title>Clinical infectious diseases</title><subject>Correspondence</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqljEtOwzAQQC0EovxWXGAOgMGukzbdIJUUBBKCqq3YRk4ybY0cO3KcVmHVg8BFOE5PghdsWLMYzdM8zSPkkrNrzkbiplBlGJmzeHBATngshnQQj_hhYBYnNEpE0iOnTfPOGOcJi49JT4iYib6ITsj32DRbdOAtPKP3gVJrCnRGmRX4NcJU1uG4331ObJtrpHdamfIKZtKUtlIfGHiqZYG5peHTO6s1lrBwSmrYKr-GFxqs73TRNR6VQVhaFzxKX6HxYJcwxw06hHHReoQZNrVy0lvXwbwzpbMVQirbJlTzDtLXt6cJ5aP97uucHC2lbvDid5-R24f7RfpI6zavsCxC3Umd1U5V0nWZlSr7a4xaZyu7yRIRRdGwL_4d-AH9joXN</recordid><startdate>20210127</startdate><enddate>20210127</enddate><creator>Alencar, Julio C</creator><creator>Souza, Heraldo P</creator><general>Oxford University Press</general><scope>5PM</scope></search><sort><creationdate>20210127</creationdate><title>Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”</title><author>Alencar, Julio C ; Souza, Heraldo P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_83444723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Correspondence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alencar, Julio C</creatorcontrib><creatorcontrib>Souza, Heraldo P</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alencar, Julio C</au><au>Souza, Heraldo P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”</atitle><jtitle>Clinical infectious diseases</jtitle><date>2021-01-27</date><risdate>2021</risdate><issn>1058-4838</issn><eissn>1537-6591</eissn><cop>US</cop><pub>Oxford University Press</pub><pmid>33503234</pmid><doi>10.1093/cid/ciab056</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2021-01
issn 1058-4838
1537-6591
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8344472
source Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)
subjects Correspondence
title Answer to Letter Concerning the Paper “Double-Blind, Randomized, Placebo-Controlled Trial with N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19”
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T20%3A59%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Answer%20to%20Letter%20Concerning%20the%20Paper%20%E2%80%9CDouble-Blind,%20Randomized,%20Placebo-Controlled%20Trial%20with%20N-acetylcysteine%20for%20Treatment%20of%20Severe%20Acute%20Respiratory%20Syndrome%20Caused%20by%20COVID-19%E2%80%9D&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Alencar,%20Julio%20C&rft.date=2021-01-27&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciab056&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_8344472%3C/pubmedcentral%3E%3Cgrp_id%3Ecdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_83444723%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33503234&rfr_iscdi=true